Eli Lilly and Company (LLY) – Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Eli Lilly and Company (NYSE: LLY) in the last few weeks:

• 10/20/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 10/17/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/15/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
• 10/12/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $1,500.00 price target on the stock.
• 10/8/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,410.00 to $1,440.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Eli Lilly and Company had its price target raised by Morgan Stanley from $1,419.00 to $1,430.00. They now have an “overweight” rating on the stock.
• 10/1/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/28/2026 – Eli Lilly and Company had its price target raised by JPMorgan Chase & Co. from $1,400.00 to $1,500.00. They now have an “overweight” rating on the stock.
• 9/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by TD Cowen. They now have a $1,250.00 price target on the stock.
• 9/18/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,273.00 to $1,284.00. They now have a “buy” rating on the stock.
• 9/17/2026 – Eli Lilly and Company had its price target raised by The Goldman Sachs Group, Inc. from $1,367.00 to $1,371.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Eli Lilly and Company was given a new $1,400.00 price target by Berenberg Bank. They now have a “buy” rating on the stock.
• 9/15/2026 – Eli Lilly and Company was upgraded by Berenberg Bank from “hold” to “buy”. They now have a $1,400.00 price target on the stock.
• 9/10/2026 – Eli Lilly and Company had its price target raised by HSBC Holdings plc from $850.00 to $940.00. They now have a “reduce” rating on the stock.
• 9/9/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by BMO Capital Markets.
• 9/1/2026 – Eli Lilly and Company was upgraded by BMO Capital Markets from “outperform” to “buy”.
• 8/26/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 8/23/2026 – Eli Lilly and Company was downgraded by Wall Street Zen from “strong-buy” to “buy”.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.